What is Celyad Oncology S.A. (CYAD)?

Celyad Oncology S.A. (CYAD) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of CYAD?

The current price of CYAD is $0.47. Prices are updated in real time on Stocks360.

What is CYAD's price-to-earnings (PE) ratio?

CYAD's trailing twelve-month PE ratio is -3.00, based on current price and earnings per share data available on Stocks360.

What is CYAD's market capitalization?

CYAD's market capitalization is $14,238,462.00, placing it in the small-cap tier.

Celyad Oncology S.A. (CYAD)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.47

Market Cap

$14.24M

PE (TTM)

-3.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.69

Day Range

$0.47 – $0.53

52-wk Range

$0.15 – $3.07

Avg Volume

N/A

Volume

49.00K

Celyad Oncology S.A. (CYAD) is a publicly traded company in the Healthcare sector. Latest price: $0.47. Market cap $14.24M. Trailing PE -3.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 24, 2021

EPS $0.43 vs est. $-1.17

Beat by $1.60

Proprietary Signals

Signal snapshot temporarily unavailable.

About Celyad Oncology S.A.

Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials. CYAD-101, an allogeneic CAR-T cell therapy, is currently undergoing Phase 1b trials for patients with metastatic colorectal cancer. Another allogeneic, shRNA-based CAR-T candidate, CYAD-211, is in Phase 1 for individuals suffering from relapsed/refractory multiple myeloma. Additionally, CYAD-02, an autologous CAR-T therapy, is being evaluated in Phase 1 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, Celyad is developing CYAD-203. This is a non-gene edited allogeneic CAR-T candidate engineered to co-express the cytokine interleukin-18 (IL-18) alongside natural killer group 2D ligands (NKG2D), targeting solid tumors. Celyad has also forged strategic alliances. It holds a licensing agreement with Novartis International AG concerning US patents for allogeneic CAR-T cell technology. Furthermore, the company has established research and development collab…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.00×
P/S (TTM)	68.30×
P/B	2.76×
P/FCF (TTM)	-0.79×
EV / EBITDA	-1.19×
EV / Sales	36.33×
Earnings Yield	-33.52%
Free Cash Flow Yield	-126.74%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$6.76M
Revenue (TTM)	$186.00K
Net Income (TTM)	-$4.26M
Free Cash Flow (TTM)	-$16.14M
Net Debt	-$5.95M
Working Capital	$8.19M
Gross Margin	93.55%
Operating Margin	-3149.46%
Net Margin	-3131.18%
Return on Equity	-109.67%
Return on Invested Capital	-43.37%